Plasmid-deficient Chlamydia muridarum fail to induce immune pathology and protect against oviduct disease

Journal of Immunology

Volumn 179, Issue 6, 2007, Pages 4027-4034

  O'Connell, Catherine M ^a,e   Ingalls, Robin R ^b   Andrews Jr , Charles W ^c   Scurlock, Amy M ^a,d   Darville, Toni ^a,d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Milstead Pathology PC   (United States)

^d ARKANSAS CHILDREN S HOSPITAL RESEARCH INSTITUTE   (United States)

^e CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOLL LIKE RECEPTOR 2; EPITOPE; TLR2 PROTEIN, MOUSE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHLAMYDIA; CHLAMYDIASIS; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; IMMUNE RESPONSE; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALPINGITIS; TH1 CELL; UTERINE TUBE DISEASE; ANIMAL; C3H MOUSE; CELL LINE; CLASSIFICATION; GENETICS; GYNECOLOGIC DISEASE; HUMAN; IMMUNIZATION; IMMUNOLOGY; INNATE IMMUNITY; MICROBIOLOGY; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; PLASMID; SIGNAL TRANSDUCTION; UTERINE TUBE;

ANIMALS; CELL LINE; CELL LINE, TRANSFORMED; CHLAMYDIA INFECTIONS; CHLAMYDIA MURIDARUM; EPITOPES, T-LYMPHOCYTE; FALLOPIAN TUBES; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; IMMUNITY, NATURAL; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED C3H; PHENOTYPE; PLASMIDS; SIGNAL TRANSDUCTION; TH1 CELLS; TOLL-LIKE RECEPTOR 2;

EID: 35748960243     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.6.4027     Document Type: Article

References (51)

1. Resnikoff, S., D. Pascolini, D. Etya'ale, I. Kocur, R. Pararajasegaram, G. P. Pokharel, and S. P. Mariotti. 2004. Global data on visual impairment in the year 2002. Bull. W. H. O. 82: 844-851.
2. WHO. 2001. World Health Organization (WHO): global prevalence and incidence of selected curable sexually transmitted infections: overview and estimates. WHO/DCS/CSR/EDC/2001.10.
3. Wasserheit, J. N., T. A. Bell, N. B. Kiviat, P. Wolner-Hanssen, V. Zabriskie, D. Kirby, E. C. Prince, K. K. Holmes, W. E. Stamm, and D. A. Eschenbach. 1986. Microbial causes of proven pelvic inflammatory disease and efficacy of clindamycin and tobramycin. Ann. Intern. Med. 104: 187-193.
4. Cates, W., Jr., and J. N. Wasserheit. 1991. Genital chlamydial infections: epidemiology and reproductive sequelae. Am. J. Obstet. Gynecol. 164: 1771-1781.
5. Stamm, W. E., M. E. Guinan, C. Johnson, T. Starcher, K. K. Holmes, and W. M. McCormack. 1984. Effect of treatment regimens for Neisseria gonorrhoeae on simultaneous infection with Chlamydia trachomatis. N. Engl. J. Med. 310: 545-549.
6. Westrom, L., R. Joesoef, G. Reynolds, A. Hagdu, and S. E. Thompson. 1992. Pelvic inflammatory disease and fertility: a cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex. Transm. Dis. 19: 185-192.
7. Katz, B. P., B. E. Batteiger, and R. B. Jones. 1987. Effect of prior sexually transmitted disease on the isolation of Chlamydia trachomatis. Sex. Transm. Dis. 14: 160-164.
8. Rank, R. G., M. M. Sanders, and D. L. Patton. 1995. Increased incidence of oviduct pathology in the guinea pig after repeat vaginal inoculation with the chlamydial agent of guinea pig inclusion conjunctivitis. J. Sex. Transm. Dis. 22: 48-54.
9. Morrison, R. P., and R. G. Rank. 2000. Chlamydial sequelae: mechanisms of immune damage in trachoma and genital tract infections. In Effects of Microbes on the Immune System. M. W. Cunningham and R. S. Fujinami, eds. Lippincott Williams & Wilkens, Philadelphia, pp. 41-55.
10. Patton, D. L., C. C. Kuo, S. P. Wang, and S. A. Halbert. 1987. Distal tubal obstruction induced by repeated Chlamydia trachomatis salpingeal infections in pig-tailed macaques. J. Infect. Dis. 155: 1292-1299.
11. Patton, D. L., and C. C. Kuo. 1989. Histopathology of Chlamydia trachomatis salpingitis after primary and repeated reinfections in the monkey subcutaneous pocket model. J. Reprod. Fertil. 85: 647-656.
12. Tuffrey, M., F. Alexander, and D. Taylor-Robinson. 1990. Severity of salpingitis in mice after primary and repeated inoculation with a human strain of Chlamydia trachomatis. J. Exp. Pathol. 71: 403-410.
13. Brunham, R. C., and J. Rey-Ladino. 2005. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat. Rev. Immunol. 5: 149-161.
14. Su, H., R. Morrison, R. Messer, W. Whitmire, S. Hughes, and H. D. Caldwell. 1999. The effect of doxycycline treatment on the development of protective immunity in a murine model of chlamydial genital infection. J. Infect. Dis. 180: 1252-1258.
15. Brunham, R. C., J. Kimani, J. Bwayo, G. Maitha, I. Maclean, C. Yang, C. Shen, S. Roman, N. J. Nagelkerke, M. Cheang, and F. A. Plummer. 1996. The epidemiology of Chlamydia trachomatis within a sexually transmitted diseases core group. J. Infect. Dis. 173: 950-956.
16. Kimani, J., I. W. Maclean, J. J. Bwayo, K. MacDonald, J. Oyugi, G. M. Maitha, R. W. Peeling, M. Cheang, N. J. Nagelkerke, F. A. Plummer, and R. C. Brunham. 1996. Risk factors for Chlamydia trachomatis pelvic inflammatory disease among sex workers in Nairobi, Kenya. J. Infect. Dis. 173: 1437-1444.
17. Holland, M. J., R. L. Bailey, D. J. Conway, F. Culley, G. Miranpuri, G. I. Byrne, H. C. Whittle, and D. C. Mabey. 1996. T helper type-1 (Th1)/Th2 profiles of peripheral blood mononuclear cells (PBMC); responses to antigens of Chlamydia trachomatis in subjects with severe trachomatous scarring. Clin. Exp. Immunol. 105: 429-435.
18. Faal, N., R. L. Bailey, I. Sarr, H. Joof, D. C. Mabey, and M. J. Holland. 2005. Temporal cytokine gene expression patterns in subjects with trachoma identify distinct conjunctival responses associated with infection. Clin. Exp. Immunol. 142: 347-353.
19. Morrison, R. P., K. Feilzer, and D. B. Tumas. 1995. Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection. Infect. Immun. 63: 4661-4668.
20. Morrison, R. P., and H. D. Caldwell. 2002. Immunity to murine chlamydial genital infection. Infect. Immun. 70: 2741-2751.
21. Ramsey, K. H., and R. G. Rank. 1990. The role of T cell subpopulations in resolution of chlamydial genital infection of mice. In Chlamydial Infections. W. R. Bowie, H. D. Caldwell, R. P. Jones, P.-A. Mardh, G. L. Ridgway, J. Schachter, W. E. Stamm, and M. E. Ward, eds. Cambridge University Press, New York, pp. 241-251.
22. Ramsey, K. H., and R. G. Rank. 1991. Resolution of chlamydial genital infection with antigen-specific T-lymphocyte lines. Infect. Immun. 59: 925-931.
23. Stephens, R. S. 2003. The cellular paradigm of chlamydial pathogenesis. Trends Microbiol. 11: 44-51.
24. Brunham, R. C., and R. W. Peeling. 1994. Chlamydia trachomatis antigens: role in immunity and pathogenesis. Infect. Agents Dis. 3: 218-233.
25. Ramsey, K. H., I. M. Sigar, J. H. Schripsema, N. Shaba, and K. P. Cohoon. 2005. Expression of matrix metalloproteinases subsequent to urogenital Chlamydia muridarum infection of mice. Infect. Immun. 73: 6962-6973.
26. Shah, A. A., J. H. Schripsema, M. T. Imtiaz, I. M. Sigar, J. Kasimos, P. G. Matos, S. Inouye, and K. H. Ramsey. 2005. Histopathologic changes related to fibrotic oviduct occlusion after genital tract infection of mice with Chlamydia muridarum. Sex. Transm. Dis. 32: 49-56.
27. Medzhitov, R., and C. Janeway, Jr. 2000. The Toll receptor family and microbial recognition. Trends Microbiol. 8: 452-456.
28. Darville, T., J. M. O'Neill, C. W. Andrews, Jr., U. M. Nagarajan, L. Stahl, and D. M. Ojcius. 2003. Toll-like receptor-2, but not Toll-like receptor-4, is essential for development of oviduct pathology in chlamydial genital tract infection. J. Immunol. 171: 6187-6197.
29. Nigg, C. 1942. An unidentified virus which produces pneumonia and systemic infection in mice. Science 95: 49-50.
30. O'Connell, C. M., and K. M. Nicks. 2006. A plasmid-cured Chlamydia muridarum strain displays altered plaque morphology and reduced infectivity in cell culture. Microbiology 152: 1601-1607.
31. Darville, T., C. W. Andrews, Jr., K. K. Laffoon, W. Shymasani, L. R. Kishen, and R. G. Rank. 1997. Mouse strain-dependent variation in the course and outcome of chlamydial genital tract infection is associated with differences in host response. Infect. Immun. 65: 3065-3073.
32. O'Connell, C. M., I. A. Ionova, A. J. Quayle, A. Visintin, and R. R. Ingalls. 2006. Localization of TLR2 and MyD88 to Chlamydia trachomatis inclusions: evidence for signaling by intracellular TLR2 during infection with an obligate intracellular pathogen. J. Biol. Chem. 281: 1652-1659.
33. Latz, E., A. Visintin, E. Lien, K. A. Fitzgerald, B. G. Monks, E. A. Kurt-Jones, D. T. Golenbock, and T. Espevik. 2002. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the Toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J. Biol. Chem. 277: 47834-47843.
34. Ivanova, E. H., L. Michailova, Z. Stefanova, H. Neychev, S. Radoevska, and J. Gumpert. 1997. Effect of Escherichia coli L-form cytoplasmic membranes on the interaction between macrophages and Lewis lung carcinoma cells: scanning electron microscopy. FEMS Immunol. Med. Microbiol. 17: 27-36.
35. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176: 1693-1702.
36. De la Maza, L., S. Pal, A. Khamesipour, and E. M. Peterson. 1994. Intravaginal inoculation of mice with the Chlamydia trachomatis mouse pneumonitis biovar results in infertility. Infect. Immun. 62: 2094-2097.
37. Zhang, D., X. Yang, H. Lu, G. Zhong, and R. C. Brunham. 1999. Immunity to Chlamydia trachomatis mouse pneumonitis induced by vaccination with live organisms correlates with early granulocyte-macrophage colony-stimulating factor and interleukin-12 production and with dendritic cell-like maturation. Infect. Immun. 67: 1606-1613.
38. Fichorova, R. N., A. O. Cronin, E. Lien, D. J. Anderson, and R. R. Ingalls. 2002. Response to Neisseria gonorrhoeae by cervicovaginal epithelial cells occurs in the absence of Toll-like receptor 4-mediated signaling. J. Immunol. 168: 2424-2432.
39. Matsumoto, A., H. Izutsu, N. Miyashita, and M. Ohuchi. 1998. Plaque formation by and plaque cloning of Chlamydia trachomatis biovar trachoma. J. Clin. Microbiol. 36: 3013-3019.
40. Cook, D. N., D. S. Pisetsky, and D. A. Schwartz. 2004. Toll-like receptors in the pathogenesis of human disease. Nat. Immunol. 5: 975-979.
41. Hawn, T. R., H. Wu, J. M. Grossman, B. H. Hahn, B. P. Tsao, and A. Aderem. 2005. A stop codon polymorphism of Toll-like receptor 5 is associated with resistance to systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA 102: 10593-10597.
42. Hawn, T. R., S. J. Dunstan, G. E. Thwaites, C. P. Simmons, N. T. Thuong, N. T. Lan, H. T. Quy, T. T. Chau, N. T. Hieu, S. Rodrigues, et al. 2006. A polymorphism in Toll-interleukin 1 receptor domain containing adaptor protein is associated with susceptibility to meningeal tuberculosis. J. Infect. Dis. 194: 1127-1134.
43. Hawn, T. R., A. Verbon, M. Janer, L. P. Zhao, B. Beutler, and A. Aderem. 2005. Toll-like receptor 4 polymorphisms are associated with resistance to Legionnaires' disease. Proc. Natl. Acad. Sci. USA 102: 2487-2489.
44. Kiechl, S., E. Lorenz, M. Reindl, C. J. Wiedermann, F. Oberhollenzer, E. Bonora, J. Willeit, and D. A. Schwartz. 2002. Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med. 347: 185-192.
45. Mullick, A. E., P. S. Tobias, and L. K. Curtiss. 2005. Modulation of atherosclerosis in mice by Toll-like receptor 2. J. Clin. Invest. 115: 3149-3156.
46. Mueller, M., S. Postius, J. G. Thimm, K. Gueinzius, I. Muehldorfer, and C. Hermann. 2004. Toll-like receptors 2 and 4 do not contribute to clearance of Chlamydophila pneumoniae in mice, but are necessary for the release of monokines. Immunobiology 209: 599-608.
47. Naiki, Y., K. S. Michelsen, N. W. J. Schroder, R. Alsabeh, A. Slepenkin, W. Zhang, S. Chen, B. Wei, Y. Bulut, M. H. Wong, et al. 2005. MyD88 is pivotal for the early inflammatory response and subsequent bacterial clearance and survival in a mouse model of Chlamydia pneumoniae pneumonia. J. Biol. Chem. 280: 29242-29249.
48. Rodriguez, N., N. Wantia, F. Fend, S. Durr, H. Wagner, and T. Miethke. 2006. Differential involvement of TLR2 and TLR4 in host survival during pulmonary infection with Chlamydia pneumoniae. Eur. J. Immunol. 36: 1145-1155.
49. Pal, S., E. M. Peterson, R. Rappuoli, G. Ratti, and L. M. De La Maza. 2006. Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge. Vaccine 24: 766-775.
50. Murthy, A. K., J. P. Chambers, P. A. Meier, G. Zhong, and B. P. Arulanandam. 2007. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous γ interferon production. Infect. Immun. 75: 666-676.
51. Dean, D., E. Oudens, G. Bolan, N. Padian, and J. Schachter. 1995. Major outer membrane protein variants of Chlamydia trachomatis are associated with severe upper genital tract infections and histopathology in San Francisco. J. Infect. Dis. 172: 1013-1022.